+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sumitomo Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 59 Pages
  • August 2024
  • GlobalData
  • ID: 5649265
Sumitomo Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sumitomo Pharma Co Ltd (Sumitomo Pharma), formerly Sumitomo Dainippon Pharma Co Ltd, develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology, and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. The company offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Pharma has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Pharma Co Ltd Key Recent Developments

  • Jul 10, 2023: Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities
  • Apr 03, 2023: Sumitomo Pharma subsidiary companies in the U.S., including sumitovant and its wholly owned subsidiaries, to combine and form Sumitomo Pharma America
  • Mar 23, 2023: Sumitomo Pharma and National Center for Global Health and Medicine Initiate 2nd Joint International Project on Measures against Antimicrobial Resistance (AMR) And Promoting Proper Use of Antibiotics in Vietnam
  • Jan 31, 2023: Sumitomo Pharma Announces Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Sumitomo Pharma Co Ltd - Key Facts
  • Sumitomo Pharma Co Ltd - Key Employees
  • Sumitomo Pharma Co Ltd - Key Employee Biographies
  • Sumitomo Pharma Co Ltd - Major Products and Services
  • Sumitomo Pharma Co Ltd - History
  • Sumitomo Pharma Co Ltd - Company Statement
  • Sumitomo Pharma Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Sumitomo Pharma Co Ltd - Business Description
  • Product Category: Others
  • Performance
  • Product Category: Pharmaceuticals
  • Performance
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: North America
  • Performance
  • R&D Overview
  • Sumitomo Pharma Co Ltd - Corporate Strategy
  • Sumitomo Pharma Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Sumitomo Pharma Co Ltd - Strengths
  • Sumitomo Pharma Co Ltd - Weaknesses
  • Sumitomo Pharma Co Ltd - Opportunities
  • Sumitomo Pharma Co Ltd - Threats
  • Sumitomo Pharma Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Sumitomo Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sumitomo Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Sumitomo Pharma Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 10, 2023: Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities
  • Apr 03, 2023: Sumitomo Pharma subsidiary companies in the U.S., including sumitovant and its wholly owned subsidiaries, to combine and form Sumitomo Pharma America
  • Mar 23, 2023: Sumitomo Pharma and National Center for Global Health and Medicine Initiate 2nd Joint International Project on Measures against Antimicrobial Resistance (AMR) And Promoting Proper Use of Antibiotics in Vietnam
  • Jan 31, 2023: Sumitomo Pharma Announces Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2023
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Sumitomo Pharma Co Ltd, Key Facts
  • Sumitomo Pharma Co Ltd, Key Employees
  • Sumitomo Pharma Co Ltd, Key Employee Biographies
  • Sumitomo Pharma Co Ltd, Major Products and Services
  • Sumitomo Pharma Co Ltd, History
  • Sumitomo Pharma Co Ltd, Other Locations
  • Sumitomo Pharma Co Ltd, Subsidiaries
  • Sumitomo Pharma Co Ltd, Key Competitors
  • Sumitomo Pharma Co Ltd, Ratios based on current share price
  • Sumitomo Pharma Co Ltd, Annual Ratios
  • Sumitomo Pharma Co Ltd, Interim Ratios
  • Sumitomo Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sumitomo Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Sumitomo Pharma Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Sumitomo Pharma Co Ltd, Performance Chart (2020 - 2024)
  • Sumitomo Pharma Co Ltd, Ratio Charts
  • Sumitomo Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sumitomo Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Tsumura & Co
  • Towa Pharmaceutical Co Ltd
  • Torii Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Shin Nippon Biomedical Laboratories Ltd
  • Nippon Shinyaku Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Kissei Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Astellas Pharma Inc